ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options

被引：0
|
作者：
Freye, Reimund
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷 / 11期
关键词：
D O I：
10.1159/000494601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [21] ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
    Casaluce, Francesca
    Sgambato, Assunta
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Carmine
    Napolitano, Alba
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    TARGETED ONCOLOGY, 2013, 8 (01) : 55 - 67
  • [22] ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
    Francesca Casaluce
    Assunta Sgambato
    Paolo Maione
    Antonio Rossi
    Carmine Ferrara
    Alba Napolitano
    Giovanni Palazzolo
    Fortunato Ciardiello
    Cesare Gridelli
    Targeted Oncology, 2013, 8 : 55 - 67
  • [23] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
    Yang, James C. H.
    Kim, Hye R.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki H.
    Delmonte, Angelo
    Garcia Campelo, Maria R.
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Haney, Jeff
    Kerstein, David
    Popat, Sanjay
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] The Best Treatment Sequence for Advanced NSCLC EGFR/ALK/ROS/BRAF wt
    Wolf, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S28 - S29
  • [25] Phase I trial of an ALK inhibitor for NSCLC
    Crisp, Alisa
    PERSONALIZED MEDICINE, 2012, 9 (06) : 574 - 574
  • [26] Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC
    Tanvetyanon, Tawee
    Chen, Dung-Tsa
    Gray, Jhanelle E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK plus NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
    Camidge, R.
    Kim, H. R.
    Ahn, M.
    Yang, J. C.
    Han, J.
    Lee, J.
    Hochmair, M.
    Li, J. Y.
    Chang, G.
    Lee, K.
    Gridelli, C.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D.
    Bearz, A.
    Griesinger, F.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S184 - S185
  • [29] Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC
    Schmid, S.
    Chotai, S.
    Cheng, S.
    Zhan, L.
    Balaratnam, K.
    Khan, K.
    Patel, D.
    Brown, M. C.
    Xu, W.
    Moriarty, P.
    Kaidanovich-Beilin, O.
    Shepherd, F. A.
    Sacher, A.
    Leighl, N.
    Bradbury, P.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1088 - S1088
  • [30] Brigatinib versus crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: results from the phase 3 ALTA-1L trial
    Califano, R.
    Camidge, D.
    Kim, H. -R.
    Ahn, M. -J.
    Yang, J.
    Han, J. -Y.
    Hochmair, M.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D. -W.
    Griesinger, F.
    Felip, E.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Ni, Q.
    Zhang, P.
    Popat, S.
    LUNG CANCER, 2020, 139 : S59 - S60
12345